Myriad Genetics, Inc.

Myriad Genetics, Inc.

Myriad Genetics, Inc.

Overview
Date Founded

1991

Headquarters

Corporation Trust Center,1209 Orange Street,Wilmington, DE 19801

Type of Company

Public

Employees (Worldwide)

2,400

Industries

Medical Products & Equipment
Pharmaceuticals
Biotechnology

Company Description

Our goal, at Myriad, is to make a difference in patient’s lives and for the past twenty years, the Company’s strategy has been guided by this mission. To accomplish this, we are focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties. Over the last twenty years, Myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease. Almost one million patients have already benefited from Myriad’s informative testing, which helps physicians better manage their health care. Today, Myriad continues to build on this strong tradition. We are working to expand our reach by introducing new genetic tests and molecular diagnostic tests for a number of diseases. We also are focused on extending our mission internationally, in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers

Website
Contact Data
Trying to get in touch with decision makers at Myriad Genetics, Inc.? Subscribe today to access their professional contact information.
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer, Treasurer & Executive Vice President

Executive Vice President, General Counsel & Secretary

Chief Information Officer

Chief Scientific Officer

Chief Medical Officer

President, Myriad RBM, Inc

President, Crescendo Bioscience, Inc

President, Myriad Genetic Laboratories, Inc

President, Assurex Health, Inc

Board of Directors

Former Vice President-Europe, US & International Pharmaceuticals at Pfizer, Inc.

Co-Founder at Myriad Genetics, Inc.

Advisor at Patricia Industries, Inc.

Venture Partner, Biotechnology at SV Life Sciences Advisers LLP

President & Chief Executive Officer at Myriad Genetics, Inc.

Paths to Myriad Genetics, Inc.
Potential Connections via
Relationship Science
You
Myriad Genetics, Inc.
Owners & Shareholders
Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income. They seek to achieve this objective by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, Camber may occasionally invest in other sectors if more attractive opportunities are identified.Camber employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation. The firm believes that the excessive focus on short-term returns and near term catalysts within the healthcare space often causes public market prices to greatly overreact to near term news flow. Camber takes on short-term risk in order to capitalize on attractive intermediate- to long-term opportunities. To maximize returns, they may, on occasion, employ the use of leverage.

Details Hidden

Frontier Capital Management specializing in managing growth and value equity portfolios for institutions. Their primary focus is our internally generated fundamental research. Through in-depth bottom up analysis, the firm identifies companies that they believe have the potential to show above average returns for clients' portfolios. Frontier's strategies include Small Cap Growth, Capital Appreciation, Mid Cap Growth, All Cap Research, SMID Cap Research, Small Cap Value and Mid Cap Value.Frontier's growth strategies seek long-term capital appreciation by employing a growth-at-a-reasonable price (GARP) approach to identify the best risk/reward investment ideas. They prefer to buy quality companies that are out-of-favor for short-term reasons, rather than the current market favorites. Their investment time frames are typically 2-4 years. In their value strategies, Frontier believes that the market generally overreacts, pricing many value stocks too low relative to their intrinsic value and, over time, reversion to the mean can lead to better returns in value stocks. Price-to-book is important initial screen and the firm's purchase criteria include price-to-sales and return on equity.

Details Hidden

Disciplined Growth Investors (DGI) focuses on investing in companies that are expected to yield high returns. The firm's investment approach is based on the premise that stock returns can exceed a company's fundamental growth when purchased at a discount to intrinsic value. DGI's investment process is designed to capture the full benefit of a company's growth potential over time and limit the downside if the company fails to meet expectations. DGI seeks to invest in companies that are expected to yield high returns and can be purchased at a discount to intrinsic value. Their expected holding period is 7 years. DGI offers Mid-Cap Growth Equity, Small-Cap Growth Equity, and Fixed Income investment strategies.DGI's Mid-Cap Equity portfolio seeks new stock candidates with market caps of $1 billion to $10 billion. The goal is to find stocks that meet their strict criteria of superior return on capital coupled with a competitive advantage relative to industry peers and the financial ability to meet reasonable growth objectives. DGI's minimum expected return for a new mid cap position is 12%. Initial position size in the portfolio is 1%. Position sizes are increased to 2% and 3% upon confirming evidence of the firm's thesis. Stock sales are made through a Darwinian process of allocating capital to the highest expected returns or if individual security risks become unacceptably high.DGI's Small-Cap Equity portfolio seeks new stock candidates with market caps of $50 million to $1 billion. DGI seeks to find stocks that meet their strict criteria of superior return on capital coupled with a competitive advantage relative to industry peers and the financial ability to meet reasonable growth objectives. The minimum expected return for a new position in small-caps is 15%. Initial position size in the portfolio is 1%. Position sizes are increased to 2% and 3% upon confirming evidence of the firm's thesis. Stock sales are made through a Darwinian process of allocating capital to the highest expected returns or if individual security risks become unacceptably high.DGI's fixed income strategy seeks to identify fundamental growth opportunities in specific fixed-income securities that offer relative value within the fixed-income markets. The firm's decision-making approach has both top-down (duration/ maturity positioning, yield curve risk and sector/quality risk) and bottom-up (credit research, quantitative analysis and trading) components. DGI's sell discipline is managed through a combination of inputs from their maturity, sector and individual selection decisions.

Recent Transactions
Details Hidden

Myriad Genetics, Inc. purchases Counsyl, Inc. from Goldman Sachs Private Equity Group, WP Global Partners LLC, The Founders Fund Management LLC, Felicis Ventures Management Co. LLC, NB Alternatives Advisers LLC, The Gramercy Fund LLC, Aarin Capital Partners, Pilot Growth Management LLC, Perceptive Advisors (Private Equity)

Details Hidden

Myriad Genetics, Inc. purchases Assurex Health, Inc. from Blue Chip Venture Co. Ltd., Sequoia Capital, Mayo Medical Ventures, Claremont Creek Ventures, CincyTech LLC, Queen City Angels, North Coast Angel Fund, Rev1 Ventures, Allos Ventures LLC

Details Hidden

Myriad Genetics, Inc. purchases Sividon Diagnostics GmbH from Intelligent Venture Capital Management GmbH, Creathor Venture Management GmbH

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onMyriad Genetics, Inc. purchases Assurex Health, Inc. from Blue Chip Venture Co. Ltd., Sequoia Capital, Mayo Medical Ventures, Claremont Creek Ventures, CincyTech LLC, Queen City Angels, North Coast Angel Fund, Rev1 Ventures, Allos Ventures LLC

Auditor

Advised onMyriad Genetics, Inc. issued Common Stock

Investment Advisor

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Ventures, Mohr Davidow Ventures, Calibrium AG (Venture Capital)

Chair of the Securities Practice Group

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Ventures, Mohr Davidow Ventures, Calibrium AG (Venture Capital)

Legal Advisor

Advised onMyriad Genetics, Inc. purchases Crescendo Bioscience, Inc. from Safeguard Scientifics, Inc., Kleiner Perkins Caufield & Byers LLC, Skyline Ventures, Mohr Davidow Ventures, Calibrium AG (Venture Capital)

Counsel

Advised onMyriad Genetics, Inc. purchases Sividon Diagnostics GmbH from Intelligent Venture Capital Management GmbH, Creathor Venture Management GmbH

Advisors & Consultants
Legal Advisor

Co-Chair, Intellectual Property Practice at Jones Day

Legal Advisor

Former Partner at General Catalyst Partners LLC

Legal Advisor

Former Partner at Jones Day

Clients

At WellPoint, we believe there is an important connection between our members’ health and well-being—and the value we bring our customers and shareholders. So each day we work to improve the health of our members and their communities. WellPoint is one of the nation’s largest health benefits companies, with more than 36 million members in its affiliated health plans and nearly 67 million individuals served through its subsidiaries. One in nine Americans receives coverage for their medical care through WellPoint's affiliated plans. We offer a broad range of medical and specialty products.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Humana Inc. is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people. The company operates through the following segments: Retail, Group and Specialty, Healthcare Services, and Individual Commercial. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental benefit plans such as Medicare, and State-based Medicaid contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance benefits. The Healthcare Services segment offer services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics services to other Humana businesses, as well as external health plan members, external health plans, and other employers.. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand. The company was founded by David A. Jones, Sr. and Wendell Cherry in 1961 and is headquartered in Louisville, KY.

Key Stats and Financials As of 2017
Market Capitalization
$2.94B
Total Enterprise Value
$1.73B
Earnings Per Share
$0.32
Revenue
$771M
Total Debt
$99.1M
Total Equity
$778M
Enterprise Value Sales
2.24x
TEVNet Income
79.16x
Debt TEV
0.06x
Net Profit
$21.8M
EBITDA
$132M
EBITDAMargin
17.15%
Enterprise Value EBITDAOperating
13.04x
Three Year Compounded Annual Growth Rate Of Revenue
-0.29%
Five Year Compounded Annual Growth Rate Of Revenue
9.23%
Non-Profit Donations & Grants
$10K - $25K
2015
$10K - $25K
2014
$5,000 - $10K
2013
Investments
Details Hidden

RainDance Technologies, Inc. develops and commercializes professional laboratory system. It engages in the development and manufacture of genomic tools for non-invasive liquid biopsy applications for the research, early detection, treatment of cancer, inherited and infectious diseases. The company was founded by Andrew Griffiths, Darren R. Link and Jerome Bibette in 2004 and is headquartered in Billerica, MA.

Details Hidden

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest.The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include:a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity,b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade andc) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

Details Hidden

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.Genizon has one of the largest GWAS programs worldwide, addressing many common diseases and traits. Several of these have been successfully completed, generating comprehensive maps of interacting genes, biomarkers and biological disease pathways (known as GeneMaps), providing strong validation of the power of the Company's discovery platform.Genizon has out-licensed some of the therapeutic and diagnostic rights to GeneMaps for Crohn's disease (to Genentech) and attention deficit hyperactivity disorder, endometriosis and Alzheimer's disease (disease-state diagnostic rights to Pfizer). GeneMaps have also been generated from GWAS in schizophrenia, psoriasis and longevity. GWAS are in progress for rheumatoid arthritis, Alzheimer's disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension (collectively metabolic syndrome).Genizon's technology platform and discoveries can complement current R&D programs by using human genetics to significantly enhance research and by adding value at multiple stages of the drug development process.Genizon is continually developing and enhancing its gene and biomarker discovery platform. For example, the company is assessing the role of copy number variations (CNVs) in diseases- applying new methods to ongoing large-scale GWAS in rheumatoid arthritis and metabolic syndrome, and retrospectively to previous studies.Genizon also leverages its platform and expertise by offering high throughput, high quality SNP genotyping, statistical genetics, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

Suppliers
Brooks Automation, Inc. Industrial Machinery & Manufacturing | Chelmsford, Massachusetts

Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and breadth of global services provide customers speed to market, high uptime, and rapid response, which equate to superior value in their mission-critical environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Through product development initiatives and strategic acquisition, we have expanded our reach to meet the needs of customers in the life sciences industry, analytical and research fields, and clean energy markets. When optimal productivity and high availability are factors for success, customers across the globe turn to Brooks. Brooks is a public company listed on the NASDAQ stock exchange under the symbol BRKS

Oklahoma Medical Research Foundation Investment Services & Portfolio Management | OKLAHOMA CITY , OK

Oklahoma Medical Research Foundation provides investment advice. The company was founded in 1946 and is headquartered in Oklahoma City, OK.

The Mayo Clinic Hospitals & Patient Services | MINNESOTA

Mayo Clinic provides medical care. It offers healthy living program, mayo clinic membership and health letter, medical products, population health and wellness programs, health plan administration, medical laboratory services, and continuing education for medical professionals. The company was founded by William J. Mayo in 1919 and is headquartered in Rochester, MN.

Awards & Honors
Rank #33
2012
Forbes Magazine - 50 Best Small Companies 2012
Sponsored by Forbes Media LLC